World Health Organization site
Skip Navigation Links
Home
Advanced Search
List ByExpand List By
Search Tips
UTNExpand UTN
ICTRP websiteExpand ICTRP website
Contact us
                   243 records for 37 trials found!
Trials are sometimes recorded in more than one registry. These records can refer to each other using the 'Secondary ID' field. The search portal uses these Secondary IDs to group records about the same trial together in the search results.
Each group of records referring to a trial is displayed in table that is seen by pressing the + symbol. The record with the earliest date of registration is always shown first.
 
 
 
 
  Showrecords per page     

1 2 3 4
Recruitment statusMain ID Public TitleDate of Registration
RecruitingNCT02150603
Patient-Reported Outcomes in Adults With Congenital Heart Disease
21/05/2014
Not recruitingNCT01694745
EUROpean Pain Audit In Neonates
25/09/2012
RecruitingNCT01261273
e-NOBORI Observational Registry of Nobori DES
14/12/2010
Not recruitingNCT01203605
European Surgical Outcomes Study
15/09/2010
Not recruitingNCT00990964
Attain Success Clinical Trial
Recruitment statusMain IDPublic titleDate of registration
Not RecruitingCTRI/2009/091/001072Attain Success Trial : a clinical trial to assess left-heart lead implant success and complication rate using the Medtronic leads and delivery catheters15-04-2010
06/10/2009
Not recruitingNCT00917384
Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2008-005964-15-ES"Estudio de fase 3, aleatorizado y doble ciego de IMC-1121B y el mejor tratamiento complementario (MTC) en comparación con placebo y MTC en el tratamiento del adenocarcinoma metastásico gástrico o de la unión gastroesofágica después de la progresión de la enfermedad con terapia combinada en primera línea que contenga platino o fluoropirimidina". // "A Phase 3, Randomized, Double-Blinded Study of IMC-1121B and Best Supportive Care (BSC) Versus Placebo and BSC in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First-Line Platinum- or Fluoropyrimidine-Containing Combination Therapy".23/12/2009
AuthorisedEUCTR2008-005964-15-GBStudy investigating new drug, IMC-1121B, in patients with advanced cancer of the stomach/oesophagus that has grown despite standard chemotherapy (combination of chemotherapy including platinum or fluoropyrimidine). Study has two arms. Patients will be assigned "randomly" to either arm: Arm1: 2/3 of patients receive IMC-1121B and best supportive care; Arm2: 1/3 receive an inactive substance (placebo) and best supportive care. Neither the patient nor the doctor will know the treatment arm.15/03/2010
Not RecruitingEUCTR2008-005964-15-ITA Phase 3, Randomized, Double-Blinded Study of IMC-1121B and Best Supportive Care (BSC) Versus Placebo and BSC in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First-Line Platinum- or Fluoropyrimidine-Containing Combination Therapy - ND10/12/2009
AuthorisedEUCTR2008-005964-15-MTStudy investigating new drug, IMC-1121B, in patients with advanced cancer of the stomach/oesophagus that has grown despite standard chemotherapy (combination of chemotherapy including platinum or fluoropyrimidine). Study has two arms. Patients will be assigned "randomly" to either arm: Arm1: 2/3 of patients receive IMC-1121B and best supportive care; Arm2: 1/3 receive an inactive substance (placebo) and best supportive care. Neither the patient nor the doctor will know the treatment arm.08/02/2010
Not RecruitingEUCTR2008-005964-15-CZStudy investigating new drug, IMC-1121B, in patients with advanced cancer of the stomach/oesophagus that has grown despite standard chemotherapy (combination of chemotherapy including platinum or fluoropyrimidine). Study has two arms. Patients will be assigned "randomly" to either arm: Arm1: 2/3 of patients receive IMC-1121B and best supportive care; Arm2: 1/3 receive an inactive substance (placebo) and best supportive care. Neither the patient nor the doctor will know the treatment arm.28/12/2009
Not RecruitingRBR-45nf55Evaluation of the association of removable partial denture supported by implants distal extension.23/04/2012
Not RecruitingCTRI/2010/091/001245A clinical trial to study the effects of IMC-1121B and best supportive care (BSC) versus Placebo and BSC in patients with metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first line care.13-10-2010
08/06/2009
Not recruitingNCT00915018
Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2008-007803-10-ESA Phase 3, Randomized, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast Cancer Estudio de fase 3, aleatorizado, abierto y de dos grupos, de neratinib más paclitaxel versus trastuzumab más paclitaxel como tratamiento de primera línea en el cáncer de mama localmente recurrente o metastático positivo para ErbB-229/07/2009
Not RecruitingEUCTR2008-007803-10-PTA Phase 3, Randomized, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast Cancer10/08/2009
AuthorisedEUCTR2008-007803-10-FRA Phase 3, Randomized, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast Cancer04/09/2009
AuthorisedEUCTR2008-007803-10-GRA Phase 3, Randomized, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast Cancer07/10/2009
Not RecruitingEUCTR2008-007803-10-DKA Phase 3, Randomized, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast Cancer06/11/2009
AuthorisedEUCTR2008-007803-10-MTA Phase 3, Randomized, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast Cancer01/12/2009
Not RecruitingEUCTR2008-007803-10-BGA Phase 3, Randomized, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast Cancer18/02/2010
AuthorisedEUCTR2008-007803-10-LVClinical research study comparing anti-tumor acitivty of an investigational drug (neratinib) plus paclitaxel and a combination therapy of trastuzumab (Herceptin) plus paclitaxel in patients with erbB-2 positive locally recurrent or metastatic breast cancer03/08/2009
AuthorisedEUCTR2008-007803-10-HUClinical research study comparing anti-tumor acitivty of an investigational drug (neratinib) plus paclitaxel and a combination therapy of trastuzumab (Herceptin) plus paclitaxel in patients with erbB-2 positive locally recurrent or metastatic breast cancer18/06/2009
AuthorisedEUCTR2008-007803-10-GBClinical research study comparing anti-tumor acitivty of an investigational drug (neratinib) plus paclitaxel and a combination therapy of trastuzumab (Herceptin) plus paclitaxel in patients with erbB-2 positive locally recurrent or metastatic breast cancer20/07/2009
Not RecruitingEUCTR2008-007803-10-ITA Phase 3, Randomized, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast Cancer - ND30/06/2009
Not RecruitingEUCTR2008-007803-10-DEClinical research study comparing anti-tumor acitivty of an investigational drug (neratinib) plus paclitaxel and a combination therapy of trastuzumab (Herceptin) plus paclitaxel in patients with erbB-2 positive locally recurrent or metastatic breast cancer30/06/2009
AuthorisedEUCTR2008-007803-10-BEClinical research study comparing anti-tumor acitivty of an investigational drug (neratinib) plus paclitaxel and a combination therapy of trastuzumab (Herceptin) plus paclitaxel in patients with erbB-2 positive locally recurrent or metastatic breast cancer31/07/2009
Not RecruitingEUCTR2008-007803-10-LTClinical research study comparing anti-tumor acitivty of an investigational drug (neratinib) plus paclitaxel and a combination therapy of trastuzumab (Herceptin) plus paclitaxel in patients with erbB-2 positive locally recurrent or metastatic breast cancer13/08/2009
Not RecruitingCTRI/2009/091/000942A Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast Cancer18-11-2009
04/06/2009
Not RecruitingCTRI/2009/091/000128
Study of MLN0002 in Patients With Moderate to Severe Ulcerative Colitis
29-04-2009
Not recruitingNCT00878709
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2008-007345-31-ITA Randomized Double-blind Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women With Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer - ND30/06/2009
Not RecruitingEUCTR2008-007345-31-ESA Randomized Double-blind Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women With Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer. Ensayo aleatorizado, en doble ciego y controlado con placebo, de neratinib (HKI-272) después de trastuzumab en mujeres con cáncer de mama en estadío inicial con sobreexpresión/amplificación de HER-2/neu29/07/2009
AuthorisedEUCTR2008-007345-31-FRA Randomized Double-blind Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women With Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer.07/09/2009
AuthorisedEUCTR2008-007345-31-GRA Randomized Double-blind Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women With Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer.08/10/2009
AuthorisedEUCTR2008-007345-31-MTA Randomized Double-blind Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women With Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer.29/12/2009
AuthorisedEUCTR2008-007345-31-PTA Randomized Double-blind Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women With Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer.30/08/2010
AuthorisedEUCTR2008-007345-31-GBNeratinib adjuvant study31/07/2009
AuthorisedEUCTR2008-007345-31-BGNeratinib adjuvant study18/02/2010
AuthorisedEUCTR2008-007345-31-CZNeratinib adjuvant study14/07/2009
AuthorisedEUCTR2008-007345-31-SENeratinib adjuvant study07/10/2009
AuthorisedEUCTR2008-007345-31-HUNeratinib adjuvant study18/06/2009
AuthorisedEUCTR2008-007345-31-LTNeratinib adjuvant study11/08/2009
AuthorisedEUCTR2008-007345-31-BENeratinib adjuvant study31/07/2009
AuthorisedEUCTR2008-007345-31-DKNeratinib adjuvant study16/09/2009
Not RecruitingEUCTR2008-007345-31-NLNeratinib adjuvant study01/09/2009
AuthorisedEUCTR2008-007345-31-DENeratinib adjuvant study23/06/2009
08/04/2009
Not recruitingNCT00864331
Optimization of Treatment of Advanced Nonsmall Cell Lung Cancer Using Radiotherapy and Chemotherapy
17/03/2009
    
1 2 3 4
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.2 - Version history